Search

Your search keyword '"G Zanotto"' showing total 144 results
Start Over Author "G Zanotto"
144 results on '"G Zanotto"'

1. PM and ICD trends during COVID-19 pandemic in Italy. A global analysis of the national hospital discharge database

Author

M Zecchin, E Ciminello, M Torre, E Carrani, L Sampaolo, A Proclemer, G Boriani, G Zanotto, A D'onofrio, R De Ponti, and G Sinagra

Subjects
Physiology (medical), Cardiology and Cardiovascular Medicine
Abstract

Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Italian Minister of Health. Background At the beginning of the COVID-19 emergency, important restrictions in hospital admissions for non-urgent procedures, to reduce the spread of the epidemic and to direct resources for the management of patients affected by the SARS-COV2 virus were required. Furthermore, in the same period there was a significant reduction of admissions for cardiological emergencies, too. The nationwide impact of COVID-19 pandemic on invasive procedures, such Pacemakers (PM) and Implantable Cardioverter-Defibrillators (ICD) interventions, is unknown. Purpose To evaluate the trend of PM and ICD procedures performed in Italy in the last 10 years and particularly in the pandemic period. Methods All the Italian Hospital Discharge Records (Schede di Dimissione Ospedaliera – SDO) from 2012 to 2021, sent by the Italian Ministry of Health to the National Institute of Health (NIH, Istituto Superiore di Sanità-ISS) were reviewed. Among these, only records including ICD or PM procedures, either primary or secondary, and correctly reporting patient’s age and gender, were selected. The ICD9-CM codes, single and combined, relating to PM and ICD procedures were selected a taxonomy arranged into 16 groups of procedures was defined. PM procedures were also divided in 1°implant and replacement, while ICD could be considered as total procedures only. Results From 2012 to 2019 the yearly number of total PM procedures was quite stable, ranging from 63.498 (1.069/million inhabitants) to 68.807 (1.150/million). In 2020, a reduction of total procedures (38.411, 1078/million, -11% towards 2019) and 1st implant of PM (from 52.216 to 43.962, -16%), but not PM replacement, (from 16.591 to 17.331, +4%) was observed; at beginning of pandemic period (April 2020), the drop in total PM procedures in comparison to the 2018 and 2019 average value was 49%. In 2021, an increase to values exceeding the pre-pandemic numbers, was observed (total procedures 69.330, 1170/million, 49.555 1° implants, 19.775 replacements). For ICD, a slow increase of the procedure rate was observed from 2012 (20.774, 350/million) to 2017, 24.255, 400/million); afterwards, a small reduction of implants was observed in 2018 (22.616, 378/million) and 2020 (22.355, 375/million). The drop in ICD procedures observed in April 2020, compared to the 2018 and 2019 average value, was 46%. In 2021 the rate of ICD procedures (25.384, 429/million) increased more than to the pre-pandemic values. No significant changes in PM and ICD indications were observed during the study interval. Conclusions During the first year of COVID-19 pandemic, a reduction of PM and ICD procedures was observed, especially in the first period (April 2020); for PM, no reduction of replacements was observed in 2020, while the reduction of 1° PM implant and ICD procedures was compensated by an increase of activity in 2021.

Published
2023

2. Efficacy of antibacterial envelope use in cardiac implantable electronic device infection prevention: insights from real world data

Author

M Ziacchi, M Biffi, S Iacopino, M De Silvestro, P Marchese, F Miscio, V P Caccavo, G Zanotto, A Dello Russo, L Donazzan, and G Boriani

Subjects
Physiology (medical), Cardiology and Cardiovascular Medicine
Abstract

Funding Acknowledgements Type of funding sources: None. Background Infections of Cardiac implantable electronic device (CIED) are rare but serious complications impacting patients and the whole heath care system. Recently, a significative reduction in major CIED infections within 12 months of the procedure has been showed by the use of an absorbable antibiotic-eluting envelope. The aim of the analysis is to evaluate the impact of the use of the envelope on infection-related clinical events (including pocket hematoma, infection, and systemic infection) reduction in a real word patient population Methods Data on patients underwent CIED implantation or replacement were collected prospectively in the framework of One HospitalClinicalService project. Patients were divided into two groups according to the utilization of an absorbable antibiotic-eluting envelope or the non-usage of the envelope. Results Out of 1819 patients, 872 (47.9%) were implanted with an absorbable antibiotic-eluting envelope and denoted as the Envelope group. Accordingly, 947 (52.1%) patients were categorized as the control group. As compared to control, patients with envelope had higher thrombo-embolic risk, higher BMI, lower LV ejection fraction and in general had more comorbidities. During a mean follow-up of 1.4 year, the incidence rate per 100 patients-months of infective related events were significantly greater in the control compared to the Envelope group (2.85% vs 1.26%, p< 0.001). The 48-month cumulative incidence of infective related events was 6.7% in the control and 2.9% in the Envelope group (HR:0.47; 95%CI: 0.27-0.95, p= 0.032). Fig1 When considering a subgroup of 1170 patients matched by PADIT score, the incidence of infective related events was 1.0 % (6/585) in the envelope and 3.8% (22/585) in the envelope and control group, respectively, p=0.002. Conclusions In our analysis, the use of envelope in the general CIED population was effective to reduce the risk of systemic or pocket infection, or pocket hematoma

Published
2023

3. Ventricular arrhythmias and implantable cardioverter-defibrillator therapy in women: a propensity score-matched analysis

Author

G Maglia, M Giammaria, G Zanotto, A D’onofrio, P Della Bella, M Marini, G Rovaris, S Iacopino, V Calvi, EC Pisano’, F Caravati, G Balestri, D Giacopelli, A Gargaro, and M Biffi

Subjects
Physiology (medical), Cardiology and Cardiovascular Medicine
Abstract

Funding Acknowledgements Type of funding sources: None. Introduction The implantable cardioverter-defibrillator (ICD) is an established therapy for the prevention of sudden cardiac death in selected patients. Although current guidelines apply to both women and men, there is a growing awareness that the incidence of cardiac arrhythmias and device interventions is influenced by sex. Purpose To investigate sex-specific risk of sustained ventricular arrhythmias (SVAs) and device therapies, using remote monitoring data from ICDs and cardiac resynchronization therapy defibrillators (CRT-Ds). Methods Study endpoints were time to the first appropriate SVA, time to the first appropriate device therapy for SVA, and time to the first ICD shock. Appropriateness of device-detected SVAs was adjudicated by three expert electrophysiologists. Results were compared between women and a 1:1 propensity score (PS)-matched subgroup of men. Results In a cohort of 2,532 patients with an ICD or CRT-D (median age, 70 years), 488 patients (19.3%) were women. As compared to men, women more frequently had a CRT-D (51% vs. 40%, p Conclusion In our analysis of remote monitoring data, women exhibited a lower SVA risk profile than PS-matched men in the subgroup of patients with an ICD or/and ejection fraction ≥30%.

Published
2022

4. P531Cardiac resynchronization therapy in patients with permanent atrial fibrillation: insights from the HMEA database

Author

A Rapacciuolo, F Solimene, S Iacopino, A D\\'onofrio, E Pisano\\', G Zanotto, A Curnis, A Capucci, G Senatore, C Pignalberi, G Maglia, M Santamaria, D Giacopelli, A Gargaro, and P Della Bella

Subjects
medicine.medical_specialty, business.industry, medicine.medical_treatment, Cardiac resynchronization therapy, Atrial fibrillation, medicine.disease, Physiology (medical), Internal medicine, Shock (circulatory), Heart failure, medicine, Cardiology, In patient, medicine.symptom, Cardiology and Cardiovascular Medicine, business
Abstract

Funding Acknowledgements This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Background/Introduction: The benefits of cardiac resynchronization therapy with defibrillator (CRT-D) in heart failure are well established. However, a gap of evidence is still present for patients with permanent atrial fibrillation (perm-AF) Purpose To investigate outcomes of CRT-D patients with perm-AF in terms of appropriate shock for ventricular arrhythmia and all-cause mortality in a long-term time horizon. Methods We used the Home Monitoring Expert Alliance (HMEA) database, a nationwide data repository of daily remote monitoring transmissions. The episodes with delivered shock were adjudicated by a board of 3 electrophysiologists. Results Among 1226 CRT-D patients (mean age 71.2 ± 10.0 years; 75.5% males), 276 (22.5%) had perm-AF at device implantation. These patients had more frequently rate responsive function (19.7% vs 64.1%) and higher basic rate (median value 60 bpm vs 70 bpm) as compared to all other patients (p At 5-year appropriate shock incidence was 34.2% (95% confidence interval [CI], 25.1%-45.3%) for perm-AF and 19.9% (15.6%-25.1%) for all other patients. All-cause mortality was 27.7% (17.7%-41.8%) for perm-AF and 15.6% (12.2%-19.9%) for all other patients. The age- and sex-adjusted hazard ratio between perm-AF and all other patients was 1.81 (95% CI: 1.25-2.64, p = 0.002) for appropriate shock and 0.92 (95% CI: 0.57-1.50, p = 0.748) for all-cause mortality. Conclusion Although a higher incidence of appropriate shock, perm-AF at the time of CRT-D implantation was not associated with increased long-term mortality, Abstract Figure. Appropriate shock and mortality

Published
2020

5. P6556Prevention of long-lasting atrial fibrillation through device therapy in dual-chamber pacemakers: analysis on 1384 patients of the role of Reactive ATP and atrial preventive pacing

Author

J. Comisso, Matteo Ziacchi, G. Zanotto, M. Landolina, Michele Massimo Gulizia, Andrea Grammatico, Giuseppe Ricciardi, D. Facchin, Mauro Biffi, Renato Pietro Ricci, Alessandro Proclemer, G.L. Botto, Paolo Pieragnoli, and G Boriani

Subjects
Dual Chamber Pacemaker, medicine.medical_specialty, Sinoatrial node, business.industry, Atrial fibrillation, medicine.disease, law.invention, medicine.anatomical_structure, law, Internal medicine, Heart failure, medicine, Cardiology, Artificial cardiac pacemaker, Atrium (heart), medicine.symptom, Cardiology and Cardiovascular Medicine, business, Atrial flutter, Atrial tachycardia
Abstract

Background Atrial fibrillation (AF) is the most prevalent heart rhythm disorder in clinical practice and it is associated with poor quality of life and increased risks of heart failure, dementia, stroke, and death. Moreover AF management is a huge cost for healthcare systems. AF is irregular, typically originates from the pulmonary veins, and as such, requires cardioversion to terminate persistent episodes. AF is not susceptible to pace-termination, however, the MINERVA trial has shown that AF may transform in slower organized rhythms such as atrial flutter or atrial tachycardia, which can often be terminated by atrial anticahycardia pacing (ATP); in particular by Reactive ATP, a specific ATP feature which can be re-armed when atrial arrhythmias get slower or more regular. The MINERVA trial showed that the combination of ATP, preventive atrial pacing algorithms and minimal ventricular pacing (MVP) was associated with lower progression to persistent and permanent AF, compared with standard DDD pacing mode and to MVP mode, in pacemaker patients with clinical history of AF. Purpose We aimed to confirm MINERVA trial results in real-world clinical practice and to evaluate whether AF prevention was associated with preventive atrial pacing or solely with ATP. Indeed in our project atrial preventive pacing algorithms were not enabled and the pacing mode (DDD or MVP) was chosen according to patients' AV conduction characteristics. Methods Consecutive dual-chamber pacemaker patients with sinus node disease and device detected AT/AF were prospectively followed by 30 Italian cardiologic centers in an observational research. Clinical and device data were collected and reviewed by expert cardiologists to assess AT/AF occurrence through in clinic visit and/or remote transmissions of device data. Results A total of 239 patients (73 years old, 56% male) wearing a dual-chamber pacemaker with Reactive ATP were included in the project, followed for a median observation period of 13 months and compared with 1145 patients included in the MINERVA trial followed for a median observation period of 34 months and programmed with DDD pacing mode (383 patients), MVP (389 patients) and MVP+Reactive ATP+preventive algorithms (373 patients). As shown in the following figure incidence of 7 consecutive days of AF in the patients treated by DDD/MVP+Reactive ATP in real-world clinical practice was very similar to that found in the MINERVA trial arm programmed with MVP+Reactive ATP+preventive algorithms. Incidence of AF longer than 7 days Conclusions Our analysis performed in a population of sinus node disease patients with dual-chamber pacemakers confirmed MINERVA trial results in terms of prevention of long-lasting AF episodes. In particular these results confirm the benefit associated with the use of Reactive ATP, rather than preventive atrial pacing algorithms.

Published
2019

6. P2592Combining home monitoring temporal trends and baseline patient risk profile for predicting impending heart failure hospitalizations. Results from the SELENE HF (BIO.Detect HF IV) study

Author

Fabrizio Caravati, Andrea Campana, Alessio Gargaro, Edoardo Gronda, G Zanotto, Vincenzo Russo, Calvi, Francesco Solimene, D Melissano, Antonio Rapacciuolo, L Calo, M. Viscusi, Luigi Padeletti, P Bonfanti, and Antonio D'Onofrio

Subjects
medicine.medical_specialty, business.industry, Patient risk, medicine.medical_treatment, Cardiac resynchronization therapy, medicine.disease, medicine.anatomical_structure, Heart failure, Internal medicine, Heart rate, medicine, Cardiology, Heart rate variability, Atrium (heart), Cardiology and Cardiovascular Medicine, Baseline (configuration management), business, Risk assessment
Abstract

Background/Introduction The lack of a validated method to efficiently combine information provided by Remote Monitoring (RM) of implantable defibrillators (ICD) and patient clinical profile has limited the use of RM in the prevention of worsening heart failure episodes. Purpose Our objective was to develop and validate an index combining RM temporal trends and a baseline risk score for predicting the first HF hospitalization after device implantation. Methods We prospectively enrolled 918 patients (81% male, median age 69, interquartile interval [QI], 61/76; Seattle Heart Failure Score [SHFS], 0.17, QI, −0.40/0.75) with indication to ICD (56%), or ICD with cardiac resynchronization therapy (44%). The Home Monitoring (HM) system was activated in all patients after implant to collect several technical and HF-related variables daily. Investigators were blinded to HM reports, and only received automatic alerts for critical technical issues. The primary endpoint was the first adjudicated HF hospitalization. The cohort was a posteriori 1:1 randomized in derivation and validation groups stratified by device type and primary endpoint occurrence. The SHFS was used for baseline risk assessment. Results During a median follow-up of 23 months (QI, 14/36), 62 first HF hospitalizations were adjudicated. In the derivation group, the index was constructed by combining the SHFS and temporal trends of 24-hour and rest mean heart rates, ventricular ectopic beat frequency, arrhythmic atrial burden, heart rate variability, physical exercise, and thoracic impedance. Variable selection was based on an automatic stepwise procedure, after applying appropriate transformations in variable-specific time frames to maximize the area under the receiver operating characteristics curve (AUC). The resulting index was associated to an AUC of 0.88 and an Odds Ratio of 2.72 (confidence interval [CI] 1.97–3.75, p Conclusion HM temporal trends of selected variables and the SHFS may be combined to timely and efficiently predict the first HF hospitalization after implant, with less than 1 expected per-patient false alert per year. Acknowledgement/Funding BIOTRONIK SE & Co. KG, Berlin, Germany

Published
2019

7. P5744Long-term response prediction to cardiac resynchronization therapy by acute pacing-induced changes in 3D trajectory of pacing cathode pole in coronary sinus: preliminary results of TRAJECTORIES study

Author

A Corzani, G Zanotto, Giulio Molon, Lina Marcantoni, A Rossillo, L Lanzoni, Francesco Zanon, Cristiana Corsi, Corrado Tomasi, Mauro Biffi, and Stefano Severi

Subjects
medicine.medical_specialty, business.industry, Internal medicine, medicine.medical_treatment, Trajectory, Cardiology, Cardiac resynchronization therapy, Medicine, Cardiology and Cardiovascular Medicine, business, Coronary sinus, Term (time)
Published
2018

8. 5045The effect of adaptive cardiac resynchronization therapy in reducing atrial fibrillation in heart failure patients: insights from multicenter observational experience

Author

Alessandro Capucci, Alessandro Proclemer, G Boriani, T. Infusino, Filippo Lamberti, E. Pisano, Antonello Vado, G Zanotto, Mauro Biffi, A Talarico, Saverio Iacopino, and Valerio Zacà

Subjects
medicine.medical_specialty, business.industry, Heart failure, Internal medicine, medicine.medical_treatment, medicine, Cardiac resynchronization therapy, Cardiology, Atrial fibrillation, Observational study, Cardiology and Cardiovascular Medicine, medicine.disease, business
Published
2018

9. 1355Real-world observational data confirm the efficacy of atrial antitachycardia pacing in terminating slow and regular atrial tachyarrhythmias in patients wearing implantable cardiac electronic devices

Author

Ennio Pisano, Mauro Biffi, G Boriani, Alessandro Proclemer, Alessandro Capucci, Elena Marras, Saverio Iacopino, T. Infusino, D Tarricone, Valerio Zacà, G Zanotto, and F De Rosa

Subjects
medicine.medical_specialty, business.industry, Internal medicine, medicine, Cardiology, Antitachycardia Pacing, In patient, Observational study, Cardiology and Cardiovascular Medicine, business
Published
2018

10. P1285Detection of new onset of atrial fibrillation in patients wearing a single chamber defibrillator: insights from a multicentric experience

Author

G Boriani, M Mezzetti, Giovanni Rovaris, Alessandro Capucci, Mauro Biffi, C Perrone, Maurizio Lunati, Matteo Ziacchi, G Zanotto, A Pangallo, and Corrado Tomasi

Subjects
medicine.medical_specialty, business.industry, Internal medicine, medicine, Cardiology, In patient, Atrial fibrillation, Cardiology and Cardiovascular Medicine, medicine.disease, business, Single chamber, New onset
Published
2018

12. Distribution of CII and CIII peptides in lipoprotein classes: methods and clinical significance

Author

Antonio Lupo, Gabriella Righetti, G Zanotto, Maria Stella Graziani, Luisa Zanolla, and Cristina Marchetti

Subjects
Adult, Male, medicine.medical_specialty, Apolipoprotein B, medicine.medical_treatment, Clinical Biochemistry, apolipoprotein, Coronary Disease, chemistry.chemical_compound, renal disease, Renal Dialysis, Internal medicine, medicine, Humans, Clinical significance, metabolism, Apolipoproteins C, Triglycerides, Dialysis, Aged, Apolipoproteins B, Aged, 80 and over, Apolipoprotein C-III, Triglyceride, biology, Catabolism, Biochemistry (medical), Hypertriglyceridemia, Metabolism, Middle Aged, medicine.disease, Endocrinology, chemistry, biology.protein, Kidney Failure, Chronic, Apolipoprotein C-II, Female, lipids (amino acids, peptides, and proteins), Peritoneal Dialysis, Lipoprotein
Abstract

We describe a method for measuring apolipoprotein (apo) C distribution between apo B-containing lipoprotein (apo B-LP) and non-apo B-LP. The procedure requires the precipitation of apo B-LP, the redissolution of the pellet, and the quantification of C peptides in the redissolved pellet. The ratio of apo C in non-apo B-LP to apo C in apo B-LP has been calculated for both CII and CII (R-CII and R-CIII, respectively). R-CII (0.49 +/- 0.25) and R-CIII (0.84 +/- 0.54) in patients on maintenance dialysis are significantly lower than in the control group (1.14 +/- 0.57 and 1.45 +/- 0.92, respectively), indicating that hypertriglyceridemia in these patients results from a reduced catabolism of triglyceride-rich LP (TGRLP). Patients with coronary artery disease (CAD) show a distribution of C peptides no different from the control group. Analysis of covariance reveals that the patterns of R-CII and R-CIII are not entirely predictable from the serum concentration of triglycerides. This result seems to support the hypothesis that the underlying metabolic defects involving TGRLP in dialysis patients are not the same as those in patients with CAD.

Published
1994

13. CARVEDILOL NA HIPERTROFIA CARDÍACA INDUZIDA POR ANABOLIZANTES EM COELHOS

Author

G. Zanotto, A. C. F. Meirelles, and A. F. P. F. Wouk

Subjects
medicine.medical_specialty, General Veterinary, business.industry, Cardiomyopathy, Cardiac silhouette, medicine.disease, Heart monitoring, Surgery, Muscle hypertrophy, Heart size, Trustworthiness, Internal medicine, Myocardial hypertrophy, medicine, Cardiology, business, Carvedilol, medicine.drug
Abstract

With the intention of testing the use of carvedilol for the treatment of secondary cardiovascular alterations due to the use of AAS, an experimental study was accomplished in 30 rabbits. Heart monitoring was performed through the analysis of heart silhouette obtained from a sequence of x-rays and evaluated through the program AUTOCAD 2004 â . The use of carvedilol reduced in 13% in average the secondary myocardial hypertrophy to the use of 5 mg of nandrolone decanoate, weekly, during 9 weeks, providing remodelamento of the cardiac silhouette, with reduction of the areas, cardiac perimeters and volumes, when analyzed with the aid of the AUTOCAD 2004®. The use of carvedilol decrease in 13% the hypertrophy secondary to the chronic use of nandrolone decanoate in the dosage employed of 5mg for 9 weeks, remodeling of the cardiac silhouette. A decrease of areas, perimeters and heart size was observed when analyzed with the AUTOCAD 2004 â program. The interpretation of heart remodulation with the use of AUTOCAD 2004 ® could be adopted in the veterinary medicine practice for the evaluation of the treatment of patients with long period cardiomyopathy, because its great versatility, low costs and for providing trustworthy parameters of evolution of the hipertrofic cardiomiopathy.

Published
2008

15. Ventricular arrhythmias developed by ischemic and non-ischemic heart failure patients implanted with biventricular cardioverter-defibrillators for primary or secondary prevention: The InSync ICD Italian Registry

Author

BORIANI, GIUSEPPE, M. Gasparini, M. Lunati, M. Bocchiardo, A. Vincenti, M. Landolina, G. Zanotto, A. Proclemer, L. Allaria, A. Denaro, G.Boriani, M.Gasparini, M.Lunati, M.Bocchiardo, A.Vincenti, M.Landolina, G.Zanotto, A.Proclemer, L.Allaria, and A.Denaro

Subjects
REGISTRY, biventricular cardioverter-defibrillator, PREVENTION, VENTRICULAR ARRHYTHMIAS
Published
2004

20. Improving atrial fibrillation detection and stroke prevention capability by a WEB-based application. A multicenter Italian research on AFinder application

Author

Andrea Grammatico, C. Menard, G Molon, M. S. Baccillieri, Alessandro Proclemer, A. Gentili, Franco Zoppo, G. Zanotto, Gianni Gasparini, and D. Catanzariti

Subjects
medicine.medical_specialty, business.industry, Medical record, Cardiac arrhythmia, Atrial fibrillation, medicine.disease, Comorbidity, Asymptomatic, law.invention, law, Stroke prevention, Emergency medicine, medicine, Physical therapy, Artificial cardiac pacemaker, medicine.symptom, Cardiology and Cardiovascular Medicine, business, Stroke
Abstract

Purpose: Atrial fibrillation (AF) is a common arrhythmia in patients wearing implantable cardiac devices. AF has been associated with higher risk of stroke, but, when asymptomatic and intermittent, it may remain clinically unknown, thus reducing the chances of implementing stroke prevention strategies, like oral anticoagulation therapy (OAC). Aim of our project was to measure the clinical and organizational value of a web-based application, the AFinder, in improving AF detection and OAC management in patients wearing implantable pacemakers or defibrillators. Methods: 7 Italian cardiological centres prospectively followed 472 patients via in-hospital and remote visits from January 2011 to November 2012. Remote monitoring was performed by expert nurses and cardiologists who reviewed device data transmitted via patient monitors and classified clinically relevant events as AF occurrence. A new web-based application, AFinder, was exploited to identify patients with AF through a systematic scan of device data transmitted via remote monitors. To evaluate the clinical and organizational value of AFinder, we compared the number of patients found in AF during the observation period by the remote monitoring and by AFinder application and counted the number of patients in whom the OAC therapy was implemented as a consequence of new AF documentation. Results: 472 patients (76% male, 69±10 years old) were included; 184 (39%) had AF history with a mean CHADS2 score ≥2; 208 (44%) were on OAC. During a mean remote monitoring period of 12±8 months, AF occurred in 159/472 (34%) patients, in particular 58/109 pacemaker patients and 101/363 ICD patients. AFinder application found AF also in 54 patients who were not identified as AF patients during the remote monitoring observation. Out of these 54 patients, 15 had AF history as documented by patient medical records and were already treated by OAC, 6 patients were on OAC because they had valvular prostheses or suffered thromboembolic complications, while, importantly, 33 patients had no previous history of AF and were therefore not protected by OAC; in 22/33 patients AF was not considered clinically relevant due to short duration – less than 1 hour in most patients – while OAC therapy was proposed to 11/33 patients who were considered to have clinically relevant AF and high stroke risk. Conclusions: AF is a frequent comorbidity in both pacemaker and ICD patients. AFinder application enabled us to discover additional AF patients, as compared with standard remote monitoring and to improve OAC use in accordance with available guidelines for stroke risk reduction.

Published
2013

21. 424 Differences in ventricular arrhythmias between heart failure patients implanted with biventricular ICD for primary or secondary prevention of sudden death: results of the InSync ICD Italian registry

Author

E. Gronda, I. Vicini, Giuseppe Boriani, Mario Bocchiardo, Antonio Curnis, A. Carboni, Mauro Gasparini, A. Spotti, Maurizio Lunati, and G. Zanotto

Subjects
Secondary prevention, medicine.medical_specialty, business.industry, Internal medicine, Heart failure, medicine, Cardiology, Cardiology and Cardiovascular Medicine, medicine.disease, business, Sudden death
Published
2003

22. Poster Session 1

Author

A. Deshmukh, S. S. Sharma, F. G. Gobal, S. S. Singla, P. H. Hebbar, H. P. Paydak, M. Igarashi, H. Tada, Y. Sekiguchi, H. Yamasaki, K. Kuroki, T. Machino, K. Yoshida, K. Aonuma, J. Shavadia, H. Otieno, G. Yonga, A. Jinah, J. F. Qvist, P. H. Soerensen, U. Dixen, M. A. Ramirez-Marrero, B. Perez-Villardon, D. Gaitan-Roman, M. Jimenez-Navarro, J. L. Delgado-Prieto, E. De Teresa-Galvan, M. De Mora-Martin, P. B. Hebbar, W. X. Wei, S. Bardari, M. Zecchin, R. Salame', L. Vitali Serdoz, A. Di Lenarda, N. Guerrini, G. Barbati, G. Sinagra, K. Hanazawa, K. Kaitani, Y. Nakagawa, I. Lenaerts, R. Driesen, N. Hermida, H. Heidbuchel, S. Janssens, J. L. Balligand, K. R. Sipido, R. Willems, R. Sehra, D. Krummen, C. Briggs, S. Narayan, Y. Tanaka, K. Hirao, T. Nakamura, O. Inaba, A. Yagishita, K. Higuchi, H. Hachiya, M. Isobe, E. Kallergis, E. M. Kanoupakis, H. E. Mavrakis, C. A. Goudis, N. E. Maliaraki, P. E. Vardas, K. Kiuchi, C. Piorkowski, S. Kircher, T. Gaspar, N. Watanabe, A. Bollmann, G. Hindricks, K. Wauters, A. Grosse, S. Raffa, M. Brunelli, J. C. Geller, A. P. Maggioni, L. Gonzini, G. Gussoni, G. Vescovo, M. Gulizia, S. Pirelli, G. Mathieu, G. Di Pasquale, R. Salame, S. Magnani, T. Sakamoto, K. Kumagai, E. Fuke, S. Nishiuchi, T. Hayashi, Y. Miki, S. Naito, S. Oshima, I. E. Hof, E. Vonken, B. K. Velthuis, M. Meine, R. N. W. Hauer, K. P. Loh, J. O. Na, C. U. Choi, E. J. Kim, S. W. Rha, C. G. Park, H. S. Seo, D. J. Oh, H. E. Lim, D. Wichterle, V. Bulkova, M. Fiala, J. Chovancik, J. Simek, P. Peichl, R. Cihak, J. Kautzner, A. Glick, S. Viskin, B. Belhassen, A. Navarrete, F. Conte, A. Ishti, D. Sai, M. Moran, Z. Chitovova, H. Ahmed, K. Mares, J. Skoda, L. Sediva, J. Petru, V. Y. Reddy, P. Neuzil, M. Schmidt, U. Dorwarth, A. Leber, M. Wankerl, J. Krieg, F. Straube, S. Reif, E. Hoffmann, E. Mikhaylov, V. Tikhonenko, D. Lebedev, S. Y. Shin, H. S. Yong, J. I. Choi, S. H. Kim, S. Matsuo, T. Yamane, M. Hioki, K. Ito, R. Narui, T. Date, K. Sugimoto, M. Yoshimura, S. Rolf, P. Sommer, R. Batalov, S. Popov, I. Antonchenko, T. Suslova, S. Fichtner, U. Czudnochowsky, H. L. Estner, S. Ammar, T. Reents, C. Jilek, G. Hessling, I. Deisenhofer, E. Pokushalov, A. Romanov, G. Corbucci, S. Artemenko, D. Losik, V. Shabanov, A. Turov, D. Elesin, M. Abramov, P. Sanders, P. Jais, K. Roberts-Thomson, K. Fukumoto, S. Takatsuki, T. Kimura, N. Nishiyama, Y. Aizawa, T. Sato, S. Miyoshi, K. Fukuda, Y. Roux, J. Tenkorang, P. Carroz, J. Schlaepfer, P. Pascale, A. Forclaz, M. Fromer, E. Pruvot, L. Sknouril, R. Nevralova, M. Dorda, J. Januska, R. Santi, C. Geller, K. Nakamura, K. Kasseno, K. Taniguchi, A. Wutzler, M. Huemer, A. Parwani, L. H. Boldt, D. Blaschke, R. Dietz, W. Haverkamp, B. Coutu, R. Malanuk, M. Ait Said, A. Vicentini, S. Schade, K. Ando, A. Rousseauplasse, T. Deering, B. C. Picarra, A. R. Santos, P. Dionisio, P. Semedo, R. Matos, M. Leitao, A. Jacinto, M. Trinca, C. Wan, J. Glad, S. Szymkiewicz, M. Habibovic, H. Versteeg, A. J. M. Pelle, D. A. M. J. Theuns, L. Jordaens, S. S. Pedersen, S. Pakarinen, L. Toivonen, J. Taggeselle, A. Frey, A. Birkenhagen, S. Kohler, S. K. G. Maier, N. Lobitz, S. Paule, J. Becher, G. Mustafa, A. Ibrahim, G. King, B. Foley, B. Wilkoff, R. Freedman, D. Hayes, S. Kalbfleisch, S. Kutalek, R. Schaerf, I. A. Fazal, M. Tynan, C. J. Plummer, J. M. Mccomb, A. Oto, K. Aytemir, H. Yorgun, U. Canpolat, E. B. Kaya, L. Tokgozoglu, G. Kabakci, H. Ozkutlu, S. Greenberg, F. Hamati, R. Styperek, J. Alonso, D. Peress, O. Bolanos, R. Augostini, M. Pelini, S. Zhang, S. Stoycos, S. Witsaman, K. Mowrey, J. Bremer, A. Oza, G. Ciconte, P. Mazzone, G. Paglino, A. Marzi, P. Vergara, N. Sora, S. Gulletta, P. Della Bella, M. Nagashima, M. Goya, Y. Soga, K. Hiroshima, K. Andou, K. Hayashi, Y. An, M. Nobuyoshi, A. Kutarski, B. Malecka, R. Pietura, P. Osmancik, D. Herman, P. Stros, V. Kocka, P. Tousek, H. Linkova, M. Bortnik, E. Occhetta, G. Dell'era, A. Degiovanni, L. Plebani, P. N. Marino, M. V. Gorev, D. G. Alimov, P. Raju, S. Kully, S. Ugni, S. Furniss, G. Lloyd, N. R. Patel, M. W. Richards, C. E. Warren, M. H. Anderson, M. Hero, J. L. Rey, S. Ouali, S. Azzez, S. Kacem, S. Hammas, H. Ben Salem, E. Neffeti, F. Remedi, E. Boughzela, M. B. Kronborg, P. T. Mortensen, S. H. Poulsen, J. C. Nielsen, E. N. Simantirakis, J. E. Kontaraki, E. G. Arkolaki, S. I. Chrysostomakis, E. G. Nyktari, A. P. Patrianakos, R. C. Funck, C. Harink, H. H. Mueller, S. Koelsch, B. Maisch, V. Bolzani, P. Costandi, R. E. Shehada, N. Butala, B. Coppola, M. Taborsky, P. Heinc, M. Fedorco, V. Doupal, A. Di Cori, G. Zucchelli, E. Soldati, L. Segreti, R. De Lucia, S. Viani, L. Paperini, M. G. Bongiorni, K. J. Gutleben, W. Kranig, C. Barr, M. M. Morgenstern, M. Simon, Y. H. Dalal, M. Landolina, A. Pierantozzi, T. Agricola, M. Lunati, E. Pisano', G. Lonardi, G. Bardelli, G. Zucchi, B. Thibault, M. Dubuc, E. Karst, K. Ryu, P. Paiement, M. D. Carlson, T. Farazi, H. Alhous, L. Mont, J. M. Porres, J. Alzueta, X. Beiras, I. Fernandez-Lozano, A. Macias, R. Ruiz, J. Brugada, S. M. Viani, M. Seifert, T. Schau, V. Moeller, J. Meyhoefer, C. Butter, V. Ganiere, V. Niculescu, G. Domenichini, C. Stettler, P. Defaye, H. Burri, M. Stockburger, E. De Teresa, G. Lamas, M. Desaga, C. Koenig, E. Cobo, X. Navarro, U. Wiegand, M. Blich, S. Carasso, M. Suleiman, I. Marai, L. Gepstein, M. Boulos, M. Sasov, B. Liska, P. Margitfalvi, T. Malacky, M. Svetlosak, E. Goncalvesova, R. Hatala, Y. Takaya, T. Noda, Y. Yamada, H. Okamura, K. Satomi, W. Shimizu, N. Aihara, S. Kamakura, A. Proclemer, S. Boveda, H. Oswald, P. Scipione, A. Da Costa, W. Brzozowski, A. Tomaszewski, A. Wysokinski, E. Arbelo, D. Tamborero, B. Vidal, J. M. Tolosana, M. Sitges, M. Matas, G. L. Botto, C. D. Dicandia, M. Mantica, C. La Rosa, A. D' Onofrio, G. Molon, G. Raciti, R. Verlato, P. W. X. Foley, S. Chalil, K. Ratib, R. E. A. Smith, F. Printzen, A. Auricchio, F. Leyva, R. Abu Sham'a, J. Buber, D. Luria, R. Kuperstein, M. Feinberg, H. Granit, M. Eldar, M. Glikson, K. Vondrak, E. Nof, I. Lipchenca, R.- G. Vatasescu, C. Iorgulescu, C. Caldararu, A. Vasile, S. Bogdan, D. Constantinescu, M. Dorobantu, H. Sakaguchi, A. Miyazaki, T. Yamamoto, K. Fujimoto, S. Ono, H. Ohuchi, M. Martinelli, S. Martins, R. Molina, S. Siqueira, S. A. D. Nishioka, G. L. Peixoto, R. Alkmim-Teixeira, R. Costa, M. M. Meine, A. E. Tuinenburg, P. A. Doevendans, J. Denollet, K. Goscinska-Bis, I. Zupan, H. Van Der, F. Anselme, H. Hartog, M. Block, A. Borri, L. Padeletti, M. Toniolo, G. Zanotto, A. Rossi, E. Raytcheva, L. Tomasi, C. Vassanelli, I. Fernandez Lozano, C. Mitroi, J. Toquero Ramos, V. Castro Urda, V. Monivas Palomero, A. Corona Figueroa, L. Ruiz Bautista, L. Alonso Pulpon, A. S. Jadidi, F. Sacher, A. S. Shah, D. Scherr, N. Derval, M. Hocini, M. Haissaguerre, S. Castrejon Castrejon, C. Largo-Aramburu, J. Sachar, E. Gang, A. Estrada, D. Doiny, E. De Miguel, J. L. Merino, N. Trevisi, A. Ricco, F. Petracca, F. Baratto, A. Bisceglie, G. Maccabelli, A. El-Damaty, J. Sapp, J. Warren, P. Macinnis, M. Horacek, B. Dinov, R. Schoenbauer, F. Braunschweig, A. Arya, D. Andreu, A. Berruezo, J. T. Ortiz, E. Silva, T. M. De Caralt, J. Fernandez-Armenta, A. Perez-Silva, M. Ortega, J. L. Lopez-Sendon, F. Regoli, F. Faletra, G. Nucifora, E. Pasotti, T. Moccetti, C. Klersy, M. Casella, A. Dello Russo, M. Moltrasio, M. Zucchetti, G. Fassini, L. Di Biase, A. Natale, C. Tondo, N. Matsuhashi, H. J. Weig, G. Kerst, S. Weretk, P. Seizer, M. P. Gawaz, J. Schreieck, G. Sarquella-Brugada, F. Prada, C. M. Salling, C. Kolb, M. Pytkowski, A. Maciag, M. Farkowski, A. Jankowska, I. Kowalik, A. Kraska, H. Szwed, P. Maury, A. Duparc, P. Mondoly, A. Rollin, R. Pap, M. Kohari, G. Bencsik, A. Makai, L. Saghy, T. Forster, E. Ebrille, M. Scaglione, C. Raimondo, D. Caponi, P. Di Donna, A. Blandino, S. D. L. Delcre, F. Gaita, I. Roca Luque, L. D. S. Dos, N. R. G. Rivas, A. P. D. Pijuan, J. Perez, J. Casaldaliga, D. G. D. Garcia-Dorado, A. M. M. Moya, H. Sato, T. Yagi, T. Yambe, F. Streitner, C. Dietrich, E. Mahl, N. Schoene, C. Veltmann, M. Borggrefe, J. Kuschyk, P. P. Sadarmin, K. C. K. Wong, K. Rajappan, Y. Bashir, T. R. Betts, C. Leclercq, R. Martins, J. C. Daubert, P. Mabo, M. Koide, G. Hamano, T. Taniguchi, M. Yamato, N. Sasaki, K. Hirooka, Y. Ikeda, Y. Yasumura, W. Dichtl, T. Wolber, U. Paoli, S. Bruellmann, T. Berger, M. Stuehlinger, F. Duru, F. Hintringer, E. Kanoupakis, H. Mavrakis, E. Koutalas, I. Saloustros, C. Goudis, G. Chlouverakis, P. Vardas, J. M. Herre, M. Saeed, L. Saberi, S. Neuman, K. Yamaji, M. Iwabuchi, A. Baranchuk, F. Femenia, R. Miranda Hermosilla, J. C. Lopez Diez, J. L. Serra, M. Valentino, E. Retyk, N. Galizio, W. Kwasniewski, A. Filipecki, W. Orszulak, D. Urbanczyk-Swic, M. Trusz - Gluza, O. Piot, B. Degand, A. Donofrio, P. Scanu, A. Quesada, A. Kloppe, D. Mijic, H. Bogossian, M. Zarse, B. Lemke, J. Tyler, G. Comfort, T. F. Deering, A. E. Epstein, S. M. G. Greenberg, D. S. Goldman, J. Rhude, J. P. Majewski, J. Lelakowski, I. Tomala, C. M. Santos, R. S. Miranda, P. J. Sousa, D. M. Cavaco, P. P. Adragao, R. E. Knops, A. A. Wilde, M. Belhameche, J. S. Hermida, E. Dovellini, G. Frohlig, P. Siot, G. Z. Duray, C. W. Israel, J. Brachmann, K. H. Seidl, M. Foresti, F. Birkenhauer, S. H. Hohnloser, C. Ferreira, P. Mateus, H. Ribeiro, S. Carvalho, A. Ferreira, J. Moreira, W. Kadro, H. Rahim, M. Turkmani, M. Abu Lebdeh, A. Altabban, N. Cerrato, S. Rivera, F. Scazzuso, G. Albina, A. Klein, R. Laino, V. Sammartino, A. Giniger, T. Kvantaliani, M. Akhvlediani, M. Namdar, J. Steffel, S. Jetzer, F. Bayrak, G. B. Chierchia, R. Jenni, P. Brugada, Z. Bakos, M. M. Medvedev M, J. C. Jonas Carlsson, F. H. Fredrik Holmqvist, P. P. Pyotr Platonov, T. Nurbaev, M. Pirnazarov, A. Nikishin, P. Aagaard, A. Sahlen, L. Bergfeldt, E. Simeonidou, S. Kastellanos, C. Varounis, C. Michalakeas, C. Koniari, A. Nikolopoulou, M. Anastasiou-Nana, Y. Furukawa, T. Yamada, T. Morita, K. Tanaka, Y. Iwasaki, M. Kawasaki, Y. Kuramoto, M. Fukunami, C. Blanche, N. Tran, F. Rigamonti, M. Zimmermann, E. Okisheva, D. Tsaregorodtsev, V. Sulimov, D. Novikova, T. Popkova, E. Udachkina, Y. Korsakova, A. Volkov, A. Novikov, E. Alexandrova, E. Nasonov, P. Arsenos, K. Gatzoulis, G. Manis, P. Dilaveris, T. Gialernios, E. Kartsagoulis, S. Asimakopoulos, C. Stefanadis, M. Marocolo, O. Barbosa Neto, A. C. Carvalho, S. R. Marques Neto, G. R. Mota, P. R. B. Barbosa, A. Fernandez-Fernandez, S. Manzano Fernandez, F. J. Pastor-Perez, O. Barquero-Perez, R. Goya-Esteban, M. Salar, J. L. Rojo-Alvarez, A. Garcia-Alberola, M. Takigawa, M. Kawamura, T. Aiba, T. Sakaguchi, H. Itoh, M. Horie, T. Igarashi, J. Negishi, N. Toyota, O. Yamada, M. Papavasileiou, F. Cabrera Bueno, M. J. Molina Mora, J. Alzueta Rodriguez, A. Barrera Cordero, E. De Teresa Galvan, A. S. Revishvili, T. Dzhordzhikiya, O. Sopov, G. Simonyan, O. Lyadzhina, E. Fetisova, V. Kalinin, J. C. Balt, R. C. Steggerda, L. V. A. Boersma, M. C. E. F. Wijffels, E. F. D. Wever, J. M. Ten Berg, R. P. Ricci, L. Morichelli, A. D'onofrio, D. Vaccari, L. Calo', G. Buja, N. Rovai, A. Gargaro, J. Sperzel, G. Speca, L. Santini, J. Haarbo, K. Dubin, M. Carlson, A. Garcia Quintana, H. Mendoza-Lemes, L. Garcia Perez, S. Led Ramos, E. Caballero Dorta, M. Matinez De Espronceda, V. Piro Mastracchio, L. Serrano Arriezu, L. Sciarra, M. Marziali, E. Marras, M. Rebecchi, G. Allocca, E. Lioy, P. Delise, V. E. Santobuono, M. Iacoviello, F. Nacci, G. Luzzi, A. Puzzovivo, M. Memeo, F. Quadrini, S. Favale, M. E. Trucco, M. Arce, J. Palazzolo, W. Uribe, R. Maggi, T. Furukawa, F. Croci, A. Solano, M. Brignole, A. Lebreiro, A. Sousa, A. S. Correia, P. Lourenco, S. Oliveira, M. Paiva, J. Freitas, M. J. Maciel, N. Linker, G. Rieger, C. Garutti, N. Edvardsson, R. Salguero Bodes, M. De Riva Silva, A. Fontenla Cerezuela, M. Lopez Gil, E. Mejia Martinez, A. Jurado Roman, S. Garcia Alvarez, F. Arribas Ynsaurriaga, N. R. Petix, A. Del Rosso, V. Guarnaccia, A. Zipoli, F. Rabajoli, G. Foglia Manzillo, C. Tolardo, C. Checchinato, S. Chiaravallotti, M. Santarone, M. T. Spinnler, C. Podoleanu, A. Frigy, D. Dobreanu, C. Ginghina, and E. Carasca

Subjects
Lv function, medicine.medical_specialty, business.industry, Physiology (medical), Internal medicine, Cardiology, Medicine, Cardiology and Cardiovascular Medicine, business, Predictive value, Value (mathematics), Surgery
Abstract

was higher in the NRG (p 0.70 was the more accurate RT-MCE value to predict LV regional recovery with positive predictive value of 70% and negative predictive value of 56% (p

Published
2011

23. Poster Session 2

Author

T. Andersson, A. Magnusson, I.- L. Bryngelsson, O. Frobert, K. M. Henriksson, N. Edvardsson, D. Poci, M. Polovina, T. Potpara, M. Licina, N. Mujovic, A. Kocijancic, D. Simic, M. C. Ostojic, R. A. Providencia, A. Botelho, J. Trigo, J. Nascimento, N. Quintal, P. Mota, A. M. Leitao-Marques, R. F. Bosch, W. Kirch, L. Rosin, S. N. Willich, D. Pittrow, H. Bonnemeier, M. C. Valenza, L. Martin, T. Munoz Casaubon, G. Valenza, M. Botella, M. Serrano, B. Valenza, I. Cabrera, K. Anderson, B. S. Benzaquen, N. Koziolova, J. Nikonova, Y. Shilova, D. Scherr, S. Narayan, M. Wright, D. Krummen, A. Jadidi, P. Jais, M. Haissaguerre, M. Hocini, R. Hunter, Y. Liu, Y. Lu, W. Wang, R. J. Schilling, S. Bernstein, B. Wong, R. Rooke, C. Vasquez, R. Shah, S. Rosenberg, L. Chinitz, G. Morley, M. Bashir Choudhary, F. Holmqvist, J. Carlson, H.- J. Nilsson, P. G. Platonov, A. S. Jadidi, H. Cochet, S. Miyazaki, A. J. Shah, N. Marrouche, N. Calvo, M. Nadal, D. Andreu, D. Tamborero, F. E. Diaz, A. Berruezo, J. Brugada, L. Mont, S. Fichtner, G. Hessling, H. L. Estner, C. Jilek, T. Reents, S. Ammar, J. Wu, I. Deisenhofer, H. Nakanishi, K. Kashiwase, A. Hirata, M. Wada, Y. Ueda, J. Skoda, P. Neuzil, J. Popelova, J. Petru, L. Sediva, V. Y. Reddy, L. Uldry, A. Forclaz, N. Virag, J.- M. Vesin, L. Kappenberger, R. Sehra, C. Briggs, W.- J. Rappel, M. Janotka, M. Chovanec, K. Yamashiro, K. Takami, Y. Sakamoto, K. Satoh, T. Suzuki, H. Nakagawa, A. Romanov, E. Pokushalov, S. Artemenko, V. Shabanov, I. Stenin, D. Elesin, A. Turov, A. Yakubov, M. Hioki, S. Matsuo, K. Ito, R. Narui, S. Yamashita, K. Sugimoto, M. Yoshimura, T. Yamane, L. Di Biase, J. D. Gallinghouse, K. Rajappan, J. Kautzner, A. Dello Russo, C. Tondo, F. Lorgat, A. Natale, O. Balta, K. Buenz, M. Paessler, H. Anders, M. Horlitz, T. Deneke, L. Lickfett, I. Liberman, M. Linhart, R. Andrie, E. Mittmann-Braun, F. Stockigt, G. Nickenig, J. Schrickel, R. Tilz, A. Rillig, B. Feige, A. Metzner, A. Fuernkranz, A. Burchard, E. Wissner, F. Ouyang, T. R. Betts, M. A. Jones, K. C. K. Wong, N. Qureshi, Y. Bashir, G. Corbucci, D. Losik, V. Selina, M. A. Crandall, C. Daniels, E. Daoud, S. Kalbfleisch, H. Yamaji, T. Murakami, H. Kawamura, M. Murakami, K. Hina, S. Kusachi, G. Dakos, V. Vassilikos, S. Paraskevaidis, A. Mantziari, S. Theophylogiannakos, I. Chouvarda, I. Chatzizisis, I. Styliadis, T. Kimura, K. Fukumoto, N. Nishiyama, Y. Aizawa, Y. Fukuda, T. Sato, S. Miyoshi, S. Takatsuki, A. J. Navarrete Casas, I. Ali, F. C. Conte, M. Moran, B. G. Graham, O. Kalejs, R. Lacis, P. Stradins, A. Koris, I. Putnins, M. Vikmane, A. Lejnieks, A. Erglis, A. Estrada, A. Perez Silva, S. Castrejon, D. Doiny, J. L. Merino, A. Baranchuk, I. Greiss, C. S. Simpson, H. Abdollah, D. P. Redfearn, M. Buys-Topart, R. Nitzsche, B. Thibault, S. Kathan, C. Kolb, S. Reif, S. Schade, J. Taggeselle, A. Frey, A. Birkenhagen, S. Kohler, M. Schmidt, O. Cano Perez, F. Buendia, B. Igual, J. M. Osca, J. M. Sanchez, M. J. Sancho-Tello, J. M. Olague, A. Salvador, J. M. Tolosana, J. Fernandez-Armenta, M. Matas, M. C. Barbarin, M. Habibovic, K. C. Van Den Broek, D. A. M. J. Theuns, L. Jordaens, M. Alings, P. H. Van Der Voort, S. S. Pedersen, G. Pupita, S. Molini, M. Brambatti, A. Capucci, S. Molodykh, E. M. Idov, O. V. Belyaev, L. Segreti, E. Soldati, G. Zucchelli, A. Di Cori, S. Viani, L. Paperini, R. De Lucia, M. G. Bongiorni, L. Binner, M. Taborsky, D. Bello, H. Heuer, B. Ramza, I. Jenniskens, W. B. Johnson, M. S. Silvetti, L. Rava', M. S. Russo, C. Di Mambro, A. Ammirati, G. Gimigliano, M. Prosperi, F. Drago, A. R. Santos, B. Picarra, P. Semedo, P. Dionisio, R. Matos, M. Leitao, A. Jacinto, M. Trinca, P. Mazzone, G. Ciconte, A. Marzi, G. Paglino, P. Vergara, N. Sora, S. Gulletta, P. Della Bella, P. Koppitz, A. Fach, S. Hobbiesiefken, E. Fiehn, R. Hambrecht, J. Sperzel, M. Jung, J. Schmitt, D. Pajitnev, H. Burger, G. Goebel, W. Ehrlich, T. Walther, T. Ziegelhoeffer, V. Vancura, D. Wichterle, V. Melenovsky, M. Glikson, G. Goldenberg, A. Segev, D. Dvir, J. Kuzniec, A. Finkelstein, I. Hay, V. Guetta, W. K. Choo, S. Gupta, R. Kirkfeldt, J. Johansen, E. Nohr, M. Moller, P. Arnsbo, J. Nielsen, M. Banha, P. Stojanov, S. Raspopovic, D. Vasic, D. Savic, G. Nikcevic, V. Jovanovic, P. Defaye, B. Mondesert, A. Mbaye, R. Cassagneau, V. Gagniere, J. Jacon, V. Sanfins, H. R. Reis, J. N. Nobre, V. M. Martins, L. D. Duarte, C. M. Morais, J. C. Conceicao, M. Hero, J. L. Rey, A. Ducharme, C. Simpson, C. Stuglin, L. Blier, M. Senaratne, Y. Khaykin, A. Pinter, A. Mlynarska, R. Mlynarski, M. Sosnowski, J. Wilczek, C. Iorgulescu, S. Bogdan, D. Constantinescu, C. Caldararu, M. Dorobantu, A. Radu, R.- G. Vatasescu, S. Yusu, T. Ikeda, H. Mera, Y. Miwa, A. Abe, M. Miyakoshi, T. Tsukada, H. Yoshino, V. Nayar, P. Cantelon, A. Rawling, M. R. D. Belham, P. J. Pugh, J. Osca Asensi, O. Cano, D. Tejada, B. Munoz, M. Rodriguez, J. Olague, L. Wecke, A. Van Hunnik, T. Thompson, L. Di Carlo, M. Zdeblick, A. Auricchio, F. Prinzen, A. Doltra Magarolas, B. Bijnens, E. Silva, D. Penela, M. Sitges, P. Ofman, L. Navaravong, J. Leng, A. Peralta, P. Hoffmeister, R. Levine, J. Cook, M. Stoenescu, M. E. Tettamanti, A. Revilla Orodea, J. Lopez Diaz, L. De La Fuente Galan, R. Arnold, E. Garcia Moran, J. A. San Roman Calvar, I. Gomez Salvador, K. Nakamura, M. Takami, T. Keida, A. Mesato, S. Higa, M. Shimabukuro, H. Masuzaki, R. Proietti, A. Sagone, G. Domenichini, H. Burri, C. Valzania, M. Biffi, H. Sunthorn, G. Gavaruzzi, H. Foulkes, G. Boriani, S. Koh, W. Hou, J. Snell, J. Poore, N. Dalal, G. Bornzin, A. Kloppe, D. Mijic, H. Bogossian, I. Ninios, M. Zarse, B. Lemke, L. Guedon-Moreau, C. Kouakam, D. Klug, C. Marquie, F. Ziglio, S. Kacet, H. Mohamed Fereig Hamed, A. M. A. L. Hamdy, A. H. M. E. D. Abd El Aziz, M. R. V. A. T. Nabih, R. E. H. A. B. Hamdy, A. Yaminisaharif, G. H. Davoudi, A. Kasemisaeid, S. Sadeghian, A. Vasheghani Farahani, P. Yazdanifard, A. Shafiee, C. Alonso, C. Grimard, G. Jauvert, A. Lazarus, L. L. Mont, J. Ortiz-Perez, T. Caralt, J. Escudero, F. Perez, K. M. Griffith, R. Ferreyra, P. Urena, M. Demas, C. Muratore, H. Mazzetti, J. Guardado, M. Fernandes, V. H. Pereira, F. Canario-Almeida, F. Ferreira, B. Rodrigues, J. Almeida, A. Sokal, E. Jedrzejczyk, R. Lenarczyk, S. Pluta, O. Kowalski, P. Pruszkowska, A. Swiatkowski, Z. Kalarus, M. Heinke, B. Ismer, H. Kuehnert, T. Heinke, R. Surber, N. Osypka, D. Prochnau, H. R. Figulla, S. Iacopino, M. Landolina, A. Proclemer, L. Padeletti, V. Calvi, A. Pierantozzi, P. Di Stefano, A. Bauer, F. Bode, F. Le Gal, J. C. Deharo, M. Delay, J. Clementy, M. Kawamura, Y. Munetsugu, K. Tanno, Y. Kobayashi, D. Cannom, J. Hosoda, T. Ishikawa, K. Andoh, M. Nobuyoshi, S. Fujii, S. Shizuta, T. Isshiki, M. A. Castel, F. Perez-Villa, B. Vidal, P. Pruszkowska-Skrzep, M. Szulik, T. Kukulski, L. Gianfranchi, K. Bettiol, F. Pacchioni, P. Alboni, R. Abu Sham'a, J. Buber, E. Nof, R. Kuperstein, M. Feinberg, D. Luria, M. Eldar, K. Parks, J. R. Stone, J. P. Singh, E. Hatzinikolaou-Kotsakou, M. Kotsakou, T. H. Beleveslis, G. Moschos, E. Reppas, P. Latsios, K. Tsakiridis, A. Kazemisaeid, G. Davoodi, A. Yamini Sharif, M. Sheikhvatan, M. Toniolo, G. Zanotto, A. Rossi, L. Tomasi, C. Vassanelli, H. Versteeg, P. M. C. Mommersteeg, G. Vergara, J. Blauer, R. Ranjan, S. Vijayakumar, E. Kholmovski, N. Volland, R. Macleod, L. E. Aguinaga Arrascue, A. Bravo, P. Garcia Freire, P. Gallardo, E. Hasbani, J. Dantur, R. Quintana, P. P. Adragao, D. Cavaco, L. Parreira, K. Reis Santos, P. Carmo, R. Miranda, S. Marcelino, D. Cabrita, P. Sommer, T. Gaspar, S. Rolf, A. Arya, C. Piorkowski, G. Hindricks, E. Valles Gras, V. Bazan, L. Portillo, F. Suarez, J. Bruguera, J. Marti, Y. Huo, S. Richter, R. Schoenbauer, N. Rivas, J. Casaldaliga, I. Roca, L. Dos, J. Perez-Rodon, A. Pijuan, D. Garcia-Dorado, A. Moya, H. B. Carter, A. Garg, J. Hegrenes, H. J. Sih, L. R. Teplitsky, K. Kuroki, H. Tada, Y. Seo, T. Ishizu, M. Igawa, Y. Sekiguchi, K. Kuga, K. Aonuma, C. Rodriguez A, J. Mejias, P. Hidalgo, J. A. Hidalgo L, M. Orczykowski, P. Derejko, F. Walczak, E. Szufladowicz, P. Urbanek, R. Bodalski, K. Bieganowska, L. Szumowski, P. Peichl, R. Cihak, I. Skalsky, P. Kubus, P. Vit, L. Zaoral, R. A. Gebauer, M. Fiala, J. Janousek, K. Hiroshima, M. Goya, M. Ohe, K. Hayashi, Y. Makihara, M. Nagashima, Y. An, M. Schloesser, T. Lawrenz, D. Meyer Zu Vilsendorf, C. Strunk-Mueller, C. Stellbrink, J. Papagiannis, D. Avramidis, C. Kokkinakis, G. Kirvassilis, G. Eidelman, A. Arenal, T. Datino, F. Atienza, E. Gonzalez Torrecilla, A. Miracle, J. Hernandez, F. Fernandez Aviles, E. Ene, P. Insulander, H. Bastani, F. Braunschweig, N. Drca, G. Kenneback, J. Schwieler, J. Tapanainen, M. Jensen-Urstad, B. Andrea, E. M. A. Andrea, W. M. Maciel, L. S. Siqueira, R. C. Cosenza, F. M. Mittidieri, S. F. Farah, J. A. Atie, E. Kanoupakis, E. Kallergis, H. Mavrakis, C. Goudis, I. Saloustros, N. Malliaraki, G. Chlouverakis, P. Vardas, J. L. Bonnes, J. Jaspers Focks, S. W. Westra, M. A. Brouwer, J. L. R. M. Smeets, G. Inama, C. Pedrinazzi, F. Oliva, M. Senni, M. Zoni Berisso, S. Mostov, M. Haim, R. Nevzorov, D. Hasadi, B. Starsberg, A. Porter, J. Kuschyk, A. Schoene, F. Streitner, C. G. Veltmann, R. Schimpf, M. Borggrefe, U. Luesebrink, A. Gardiwal, H. Oswald, T. Koenig, D. Duncker, G. Klein, R. Bastiaenen, V. Batchvarov, O. Atty, J. H. Cheng, E. R. Behr, M. M. Gallagher, A. H. Starrenburg, K. Kraaier, M. F. Scholten, J. Van Der Palen, S. Adhya, L. A. Smith, T. Zhao, C. Bannister, R. H. Kamdar, M. Martinelli, S. Siqueira, R. Greco, S. A. D. Nishioka, A. A. A. Pedrosa, R. Alkmim-Teixeira, G. L. Peixoto, R. Costa, J. C. Nielsen, P. T. Mortensen, J. B. Johansen, W. Kwasniewski, A. Filipecki, D. Urbanczyk-Swic, W. Orszulak, M. Trusz - Gluza, J. Jimenez-Candil, J. Morinigo, C. Ledesma, C. Martin-Luengo, T. Vogtmann, M. Gomer, S. Stiller, V. Kuehlkamp, G. Zach, S. Loescher, S. Kespohl, G. Baumann, J. D. Snell, N. Korsun, J. R. Snell, B. Morley, R. Bharmi, Y. Nabutovsky, M. Mollerus, L. Naslund, A. Meyer, M. Lipinski, B. Libey, K. Dornfeld, A. Martin, M. Gallego, M. K. De Bie, J. B. Van Rees, C. J. Borleffs, J. Thijssen, J. W. Jukema, M. J. Schalij, L. Van Erven, E. T. Van Der Velde, T. A. Witteman, H. Foeken, T. Szili-Torok, F. Akca, K. Caliskan, F. Ten Cate, M. Michels, D. C. Cozma, L. Petrescu, C. Mornos, S. I. Dragulescu, J. A. Groeneweg, B. K. Velthuis, M. G. P. J. Cox, P. Loh, D. Dooijes, M. J. Cramer, J. M. T. De Bakker, R. N. W. Hauer, S. D. Park, S. H. Shin, S. I. Woo, J. Kwan, K. S. Park, D. H. Kim, A. Iorio, L. Vitali Serdoz, F. Brun, E. Daleffe, M. Zecchin, M. Dal Ferro, S. Santangelo, G. F. Sinagra, S. Ouali, R. Hammemi, S. Hammas, S. Kacem, R. Gribaa, E. Neffeti, F. Remedi, E. Boughzela, P. Korantzopoulos, K. Letsas, Z. Christogiannis, K. Kalantzi, A. Ntorkos, J. Goudevenos, P. W. X. Foley, L. Yung, E. Barnes, M. Kikuchi, H. Ito, F. Miyoshi, R. Pecini, J. M. Marott, G. B. Jensen, J. Theilade, T. Mine, T. Kodani, T. Masuyama, I. M. Mozos, C. Serban, C. Costea, L. Susan, P. Barthel, A. Mueller, M. Malik, G. Schmidt, O. Karakurt, H. Kilic, D. R. Munevver Sari, D. Mroczek-Czernecka, A. Z. Pietrucha, A. Borowiec, M. Wnuk, I. Bzukala, O. Kruszelnicka, E. Konduracka, J. Nessler, Y. Kikuchi, A. Meireles, C. Gomes, D. Anjo, C. Roque, A. Pinheiro Vieira, V. Lagarto, A. Hipolito Reis, S. Torres, L. Miller, G. Vedrenne, E. Bruguiere, A. Redheuil, T. Lavergne, J. Y. Le Heuzey, E. Mousseaux, A. Hersi, K. Alhabib, H. Alfaleh, K. Sulaiman, W. Almahmeed, J. Alsuwidi, H. Amin, A. Almotarreb, H. W. K. Pang, K. Michael, E. J. Pereira, P. W. Munt, M. F. Fitzpatrick, A. S. Revishvili, G. Simonyan, T. Dzhordzhikiya, O. Sopov, V. Kalinin, E. T. Locati, A. M. Vecchi, G. Cattafi, A. Sachero, M. Lunati, S. Sayah, A. Alizadeh, N. Nazari, M. Hekmat, M. Moradi, M. Zeighami, H. Ghanji, K. Suzuki, M. Takagi, K. Maeda, H. Tatsumi, P. Vieira, H. Reis, A. Toth, H. Vago, P. Takacs, E. Edes, A. Marki, G. Y. Balazs, K. Huttl, B. Merkely, F. Lainis, M. M. Buckley, E. J. Johns, C. M. Seifer, L. Daba, K. Liebrecht, W. Piwowarska, J. Toquero Ramos, E. Perez Pereira, C. Mitroi, V. Castro Urda, J. M. Fernandez Villanueva, A. Corona Figueroa, L. Hernandez Reina, I. Fernandez Lozano, A. Bartoletti, P. Bocconcelli, S. Giuli, R. Massa, C. Svetlich, G. Tarsi, F. Tronconi, E. Vitale, P. Stryjewski, M. Wegrzynowska, A. Lousinha, J. Labandeiro, E. Antunes, S. Silva, S. Alves, A. Timoteo, M. Oliveira, R. Cruz Ferreira, and J. Jedrzejczyk-Spaho

Subjects
medicine.medical_specialty, Voltage-dependent calcium channel, business.industry, medicine.drug_class, Umbilical artery, 030204 cardiovascular system & hematology, Cyclase, 3. Good health, Low testosterone levels, 03 medical and health sciences, 0302 clinical medicine, Bkca channel, Endocrinology, Physiology (medical), Internal medicine, medicine.artery, Natriuretic peptide, Medicine, 030212 general & internal medicine, Cardiology and Cardiovascular Medicine, business, Ionic Channels
Abstract

Inthelastdecadesseveralinvestigatorshavesuggestedtheassociationofandrogenswithhypertension. Recently, some studies have shown that the incidence of cardiovascular diseases is increased in men with low testosterone levels, suggesting a protective role of androgens. Hypertension is one of the mostcommonproblemsinpregnancythatcomplicates5-10 %ofpregnancies.Anincreaseofmorbidity wasobservedinbabiesfrompregnantwomenwithhypertension.However,thepathogenesisremains unclearandthislimitstheabilitytopreventandtreatthispathology.Thebeneficialeffectsofandrogens for vascular system are associated with their ability to cause vasorelaxation. Inhuman vessels, this non genomiceffectofandrogensappeartobeduetoactivationoflargeconductancecalcium-activatedpotassiumchannels(BKCa)andvoltagegatedpotassiumchannels(KV)whichisinducedbycGMPincrease andaconsequentactivationofcGMP-dependentproteinkinase(PKG).Ontheotherhand,thegenomic effects of androgens concerning ionic channels are almost unknown. Our previous studies suggested that androgens increase the expression of BKCa channels and decrease expression of L-type calcium channels (LTCC). The aim of this work was to analyze the genomic effects of androgens on theexpressionofotherproteinsinvolvedintheregulationofvascularcontractility,suchassolubleguanylate cyclase (sGC), the natriuretic peptide receptor-A (NPRA) and PKG. This study also aimed to compare the expression levels of these proteins in human umbilical artery (HUA) from normotensive andhypertensivepregnantwomen.ToachievethesegoalsrealtimePCRwasperformedusingsmooth

Published
2011

24. Hot topics: CRT and ICD therapy

Author

F. Voss, T. Kleemann, C. Strunk-Mueller, G. Buja, B. J. Gordon, L. Hoskova, H. M. S. G. Veneto Region, M. Gasparini, G. Giannola, I. Malek, R. Sheppard, P. Jurkuvenas, F. Chiusso, G. Crossley, G. Zanotto, R. Corbisiero, M. Santini, R. Zahn, J. Senges, I. Niazi, A. F. Folino, R. Ricci, M. Strauss, D. Vaccari, A. G. Stuart, K. Seidl, M. Lunati, M. Biffi, B. Coutu, D. Meyer Zu Vilsendorf, C. Love, J. Baker, I. A. Fazal, S. Worley, D. Martin, D. Exner, M. Hochadel, J. M. Mccomb, M. Landolina, G. F. Tomassoni, F. Ammirati, K. Sedlacek, B. Ramza, J. Kautzner, K. M. Teo, G. Tomassoni, S. Valsecchi, E. Marras, C. J. Plummer, C. Stellbrink, W. Kranig, M. Bertaglia, and J. O. Schwab

Subjects
medicine.medical_specialty, Hot topics, business.industry, Physiology (medical), medicine, Medical physics, Cardiology and Cardiovascular Medicine, business, Icd therapy
Published
2011

25. [Endothelial dysfunction in ischemic syndromes]

Author

C, Vassanelli, G, Menegatti, G, Destro, J, Molinari, G, Zanotto, E, Barbieri, I, Loschiavo, and P, Zardini

Subjects
Male, Myocardial Ischemia, Humans, Female, Endothelium, Vascular, Syndrome, Middle Aged, Coronary Vessels
Abstract

Several studies have shown evidence of the key role of the endothelium in modulating the tone of epicardial coronary vessels, in the different manifestations of coronary artery disease. Recently, the role of endothelium-dependent vasodilation has been focused, because clinical observations have suggested that myocardial ischemia might be caused or aggravated by inappropriate vasoconstriction of resistance vessels. An abnormal endothelium-dependent vasodilation, either of epicardial and of coronary microvasculature, has been documented in patients with syndrome X and in patients with history of hypertension and left ventricular hypertrophy. Vasoconstriction of the small coronary vessels is probably the mechanism underlying the impaired increase of coronary blood flow during atrial pacing and the wide variations of the ischemic threshold in some patients with chronic stable angina. In patients with variant angina, the endothelial function seems abnormal only in the conductance vessels. It is likely that the endothelial dysfunction of the small coronary arteries be present in many clinical situations in which a discrepancy between a mild atherosclerosis of epicardial coronary artery and signs of ischemia exists, as it has been observed early after successful angioplasty and after coronary artery reperfusion during acute myocardial infarction.

Published
1993

26. Poster Session 1: Ablation of SVT and VT

Author

N. M. S. De Groot, J. Z. Atary, N. A. Blom, J. P. Van Kuijk, M. J. Schalij, M. Tomaske, R. Candinas, M. Weiss, U. Bauersfeld, A.- A. Fassa, G. Ashrafpoor, H. Sunthorn, H. Burri, P. Gentil-Baron, D. Shah, A. P. Wijnmaalen, V. Delgado, E. R. Holman, J. J. Bax, K. Zeppenfeld, M. Kuhne, H. Oral, F. Morady, F. Bogun, B. Schwagten, T. Szili-Torok, P. Knops, G. Kimman, A. Thornton, L. Jordaens, K. Satomi, T. Roland, S. Kamakura, K. Kuck, F. Ouyang, S. Nowak, A. M. Wnuk-Wojnar, A. Hoffmann, C. Czerwinski, K. Szydlo, A. Rybicka-Musialik, I. Wozniak-Skowerska, M. Trusz-Gluza, T. Krynski, S. M. Stec, H. Hachiya, K. Hirao, T. Sasaki, K. Higuchi, M. Isobe, K. Etsadashvili, F. Hintringer, X. Stuehlinger, T. Berger, W. Dichtl, F. X. Roithinger, O. Pachinger, M. Stuehlinger, K. Tanno, T. Onuki, Y. Minoura, M. Kawamura, T. Asano, Y. Kobayashi, A. Bonet, J. Merce Klein, R. De Castro, P. Valdovinos, I. Colomer, M. I. Garcia, I. Serrano, A. Bardaji, P. Peichl, R. Cihak, R. Polasek, P. Kucera, J. Bytesnik, J. Kautzner, S. Schlueter, O. Grebe, E. V. Vester, P. Maury, J. Fourcade, A. Duparc, A. Hebrard, P. Mondoly, A. Rollin, P. Rumeau, M. Delay, B. W. L. De Boeck, A. J. Teske, F. A. A. Mohamed Hoesein, V. J. H. Van Driel, P. Loh, M. J. M. Cramer, F. W. Prinzen, P. A. F. Doevendans, E. Pokushalov, A. Romanov, A. Turov, P. Shugaev, S. Artemenko, N. Shirokova, B. Richter, M. Gwechenberger, A. Socas, G. Zorn, S. Albinni, J. Wojta, T. Binder, H. Goessinger, K. Kettering, H. Mollnau, F. Gramley, C. Weiss, A. Berkowitsch, T. Neumann, M. Kuniss, S. Zaltsberg, M. Wojcik, H. F. Pitschner, D. Wichterle, M. Peca, V. Bulkova, A. Suzuki, Y. Yamauchi, H. Okada, T. Obayashi, Y. Sekiguchi, K. Aonuma, F. Zoppo, E. Bertaglia, F. Zerbo, G. Brandolino, E. Bacchiega, L. Lickfett, B. Bellmann, M. Linhart, J. W. Schrickel, T. Lewalter, J. O. Schwab, G. Nickenig, E. L. Mittmann-Braun, P. Dabrowski, E. Kozluk, P. Stefanczyk, A. Kleinrok, G. Opolski, M. Andronache, A. Abdelaal, I. Magnin-Poull, J. Cedano, L. Groben, D. Mandry, E. Aliot, C. De Chillou, A. A. W. Mulder, M. C. E. F. Wijffels, E. F. D. Wever, L. V. A. Boersma, B. Manfai, R. Faludi, E. Fodi, P. Rausch, T. Simor, L. Sciarra, M. Rebecchi, E. De Ruvo, L. De Luca, L. M. Zuccaro, A. Fagagnini, P. Delise, L. Calo, E. Mikhaylov, Y. Van Belle, P. Janse, D. Lebedev, A. Kanidieva, D. Patel, M. Shaheen, K. Sonne, P. Mohanty, L. Di-Biase, L. Popova, D. Burkhardt, A. Natale, C. J. Mccann, B. Gal, P. Goethals, P. Peychev, P. Geelen, R.- G. Vatasescu, C. Iorgulescu, I. Ieremciuc, R. Alexandru, M. Dorobantu, P. Insulander, H. Bastani, F. Braunschweig, M. Jensen-Urstad, J. Schwieler, F. Tabrizi, G. Kenneback, C. S. A. B. A. Foldesi, A. Kardos, A. Mihalcz, P. A. L. Abraham, Z. O. L. T. A. N. Som, J. O. Z. S. E. F. Borbola, J. O. Z. S. E. F. Vanyi, T. A. M. A. S. Szili-Torok, A. Pastor Fuentes, A. Nunez, N. Tur, B. Berzal, F. G Cosio, N. Mujovic, M. Grujic, S. Mrdja, A. Kocijancic, T. Potpara, M. Polovina, B. Vujisic-Tesic, M. Petrovic, T. Hayashi, T. Furukawa, M. Kawabata, C. Lavalle, S. Ficili, M. Galeazzi, M. Russo, A. Pandozi, C. Pandozi, F. Venditti, M. Santini, K. Pavlikova, M. Psenicka, Z. Anger, A. Linhart, A. Narten, A. Gamelin, J. Mittag, S. Raffa, J.- C. Geller, D. Mocini, H. F. Groenveld, M. Rienstra, M. P. Van Den Berg, H. L. Hillege, D. J. Van Veldhuisen, I. C. Van Gelder, G. Morani, A. Manica, C. Angheben, M. A. Cicoira, L. Pozzani, L. Tomasi, G. Zanotto, C. Vassanelli, S. Ahmed, A. V. Ranchor, and A. C. P. Wiesfeld

Subjects
medicine.medical_specialty, business.industry, Physiology (medical), medicine.medical_treatment, medicine, Radiology, Session (computer science), Cardiology and Cardiovascular Medicine, Ablation, business
Published
2009

27. [Myocardial infarct and angiographically normal coronary arteries]

Author

C, Vassanelli, G, Menegatti, G, Zanotto, G, Canali, G, Morando, M, Turri, L, Zanolla, G, Destro, E, Barbieri, and G P, Nidasio

Subjects
Adult, Male, Chi-Square Distribution, Incidence, Myocardial Infarction, Humans, Coronary Disease, Female, Middle Aged, Coronary Angiography, Aged
Abstract

Myocardial infarction and normal coronary arteries is not a rare event in the ischemic heart disease. Even if the patients with acute myocardial infarction and angiographically normal coronary arteries represent a small percentage (reported incidence varies from 1% to 12%) of all patients with acute ischemic attacks, they might be useful to highlight the pathogenetic mechanisms of this syndrome. To improve the understanding of this clinical entity, we reviewed our experience of 18 patients with myocardial infarction and normal coronary arteries. They were compared with a control group of patients with similar clinical characteristics (gender, age, infarct location) and residual coronary artery stenosis. The myocardial damage was less extensive in patients without residual stenosis (peak CK-MB: 56.1 +/- 71.9 vs 126.5 +/- 87.9 IU/I, p0.05), with a better left ventricular function either global (ejection fraction: 64 +/- 11 vs 55 +/- 13%, p0.05) and regional (SD/chord: -1.36 +/- 1.20 vs -2.42 +/- 1.04, p0.02). These findings probably reflect a more prompt and complete reperfusion of the infarct related artery. Myocardial necrosis may occur without obstructive coronary artery disease by the interaction of multiple factors such as abnormal platelet aggregation, thrombus formation and localized or diffuse changes of coronary vascular tone.

Published
1991

28. [Angina due to anatomical anomalies and to functional changes in the epicardial coronary vessels]

Author

E, Barbieri, G, Destro, G, Zanotto, L, Zanolla, G, Canali, G, Morando, M, Turri, G, Menegatti, C, Vassanelli, and L, Rossi

Subjects
Electrocardiography, Chi-Square Distribution, Coronary Vessel Anomalies, Myocardial Ischemia, Humans, Prospective Studies, Coronary Angiography, Coronary Vessels, Acetylcholine, Angina Pectoris, Retrospective Studies
Abstract

Myocardial ischemia with normal coronary arteries can be due to anatomic or functional reasons. The more severe congenital coronary anomalies in the adulthood are the origin of the left main of the left coronary artery from the right aortic sinus, with a course between the aorta and the pulmonary trunk, and the origin of the left main from the pulmonary trunk. Both these anomalies can cause sudden death, usually associated with physical exertion. The coronary vasomotion of epicardial vessels depends on the interaction of several neurohumoral substances. We report the hemodynamic, angiographic and stress test data of 30 patients affected by chest pain, with myocardial ischemia and normal coronary arteries. In 8 patients the response of epicardial coronary arteries to intracoronary infusion of acetylcholine was evaluated.

Published
1991

29. Intrathoracic impedance monitored with an implantable biventricular defibrillator reduces hospitalizations in patients with heart failure

Author

G.B. Perego, G. Lonardi, Maurizio Lunati, G. Vergara, S. Valsecchi, M. Landolina, G. Zanotto, and A. Pappone

Subjects
medicine.medical_specialty, business.industry, Heart failure, Biventricular defibrillator, Internal medicine, Cardiology, Medicine, Intrathoracic impedance, In patient, Cardiology and Cardiovascular Medicine, business, medicine.disease
Published
2008

31. 205 Ventricular arrhythmias of ischemic and non-ischemic heart failure patients implanted with biventricular cardioverter-defibrillators for primary or secondary prevention: InSync ICD Italian registry

Author

Giuseppe Boriani, Alessandra Denaro, Mauro Gasparini, Maurizio Lunati, L. Allaria, Antonio Curnis, A. Vincenti, G. Zanotto, Mario Bocchiardo, and M. Landolina

Subjects
Secondary prevention, medicine.medical_specialty, business.industry, Internal medicine, Heart failure, medicine, Cardiology, Non ischemic, Cardiology and Cardiovascular Medicine, medicine.disease, business
Published
2004

35. [Random thoughts]

Author

G, ZANOTTO

Subjects
Thinking, Humans, Medicine
Published
1959

45. Contemporary Advances in Cardiac Remote Monitoring: A Comprehensive, Updated Mini-Review.

Author

Preda A, Falco R, Tognola C, Carbonaro M, Vargiu S, Gallazzi M, Baroni M, Gigli L, Varrenti M, Colombo G, Zanotto G, Giannattasio C, Mazzone P, and Guarracini F

Subjects
Humans, Arrhythmias, Cardiac diagnosis, Arrhythmias, Cardiac therapy, Monitoring, Physiologic methods, Telemedicine trends, Defibrillators, Implantable standards, Heart Failure therapy, Heart Failure diagnosis
Abstract

Over the past decade, remote monitoring (RM) has become an increasingly popular way to improve healthcare and health outcomes. Modern cardiac implantable electronic devices (CIEDs) are capable of recording an increasing amount of data related to CIED function, arrhythmias, physiological status and hemodynamic parameters, providing in-depth and updated information on patient cardiovascular function. The extensive use of RM for patients with CIED allows for early diagnosis and rapid assessment of relevant issues, both clinical and technical, as well as replacing outpatient follow-up improving overall management without compromise safety. This approach is recommended by current guidelines for all eligible patients affected by different chronic cardiac conditions including either brady- and tachy-arrhythmias and heart failure. Beyond to clinical advantages, RM has demonstrated cost-effectiveness and is associated with elevated levels of patient satisfaction. Future perspectives include improving security, interoperability and diagnostic power as well as to engage patients with digital health technology. This review aims to update existing data concerning clinical outcomes in patients managed with RM in the wide spectrum of cardiac arrhythmias and Hear Failure (HF), disclosing also about safety, effectiveness, patient satisfaction and cost-saving.

Published
2024
Full Text
View/download PDF

46. Conduction system disease management in patients candidate and/or treated for the aortic valve disease: an Italian Survey promoted by Italian Association of Arrhythmology and Cardiac Pacing (AIAC).

Author

Ziacchi M, Spadotto A, Palmisano P, Guerra F, De Ponti R, Zanotto G, Bertini M, Biffi M, and Boriani G

Subjects
Humans, Italy epidemiology, Cardiac Conduction System Disease therapy, Cardiac Conduction System Disease diagnosis, Cardiac Conduction System Disease epidemiology, Aortic Valve Disease surgery, Surveys and Questionnaires, Cardiac Pacing, Artificial methods, Cardiac Pacing, Artificial statistics & numerical data, Societies, Medical, Pacemaker, Artificial, Heart Valve Prosthesis Implantation methods, Heart Valve Prosthesis Implantation adverse effects, Female, Male, Aortic Valve surgery, Disease Management, Heart Conduction System physiopathology, Transcatheter Aortic Valve Replacement adverse effects, Transcatheter Aortic Valve Replacement methods
Abstract

Background: Conduction system disorders represent a frequent complication in patients undergoing surgical (surgical aortic valve replacement, SAVR) or percutaneous (transcatheter aortic valve implantation, TAVI) aortic valve replacement. The purpose of this survey was to evaluate experienced operators approach in this clinical condition., Methods: This survey was independently conducted by the Italian Association of Arrhythmology and Cardiac Pacing (AIAC) and it consisted of 24 questions regarding the respondents' profile, the characteristics of participating centres, and conduction disease management in different scenarios., Results: Fifty-five physicians from 55 Italian arrhythmia centres took part in the survey. Prophylactic pacemaker implantation is rare. In case of persistent complete atrioventricular block (AVB), 49% and 73% respondents wait less than one week before implanting a definitive pacemaker after SAVR and TAVI, respectively. In case of second degree AVB, the respondents wait some days more for definitive implantation. Respondents consider bundle branch blocks, in particular pre-existing left bundle branch block (LBBB), the worst prognostic factors for pacemaker implantation after TAVI. The implanted valve type is considered a relevant element to evaluate. In patients with new-onset LBBB and severe/moderate left ventricular systolic dysfunction, respondents would implant a biventricular pacemaker in 100/55% of cases, respectively., Conclusions: Waiting time before a definitive pacemaker implantation after aortic valve replacement has reduced compared to the past, and it is anticipated in TAVI vs. SAVR. Bundle branch blocks are considered the worse prognostic factor for pacemaker implantation after TAVI. The type of pacemaker implanted in new-onset LBBB patients without severe left ventricular systolic dysfunction is heterogeneous.

Published
2024
Full Text
View/download PDF

47. A global analysis of implants and replacements of pacemakers and cardioverter-defibrillators before, during, and after the COVID-19 pandemic in Italy.

Author

Zecchin M, Ciminello E, Mari V, Proclemer A, D'Onofrio A, Zanotto G, De Ponti R, Capovilla TM, Laricchiuta P, Biondi A, Sampaolo L, Pascucci S, Sinagra G, Boriani G, Carrani E, and Torre M

Subjects
Humans, Pandemics, Registries, Italy epidemiology, COVID-19 epidemiology, Pacemaker, Artificial, Defibrillators, Implantable
Abstract

At the beginning of the COVID-19 emergency, non-urgent surgical procedures had to be deferred, but also emergencies were reduced. To assess the global trend of pacemaker (PM) and implantable cardiac-defibrillator (ICD) procedures performed in Italy before, during, and after the first COVID-19 emergency, all the Italian hospital discharge records related to PM/ICD procedures performed between 2012 and 2021, sent to the National Institute of Health, were reviewed. Compared to 2019, in 2020, there was a reduction of first PM implants (52,216 to 43,962, -16%; p < 0.01), but not replacements (16,591 to 17,331, + 4%; p = 0.16). In particular, in April 2020, there was a drop of first implants (- 53,4% vs the average value of April 2018 and April 2019; p < 0.01), while the reduction of replacements was less evident (-32.6%; p = NS). In 2021, PM procedures increased to values similar to the pre-pandemic period. A reduction of ICD procedures was observed in 2020 (22,355, -7% toward 2019), mainly in April 2020 (- 46% vs April 2018/April 2019; p = 0.03). In 2021, the rate of ICD procedures increased (+ 14% toward 2020). A non-significant reduction of "urgent" procedures (complete atrioventricular block for PM and ventricular fibrillation for ICD), even in April 2020, was observed. In 2020, there was a reduction of first PM implants and ICDs, offset by increased activity in 2021. No decrease in PM replacements was observed, and the drop in "urgent" PM and ICD procedures was not statistically significant., (© 2023. The Author(s).)

Published
2024
Full Text
View/download PDF

48. REducing INFectiOns thRough Cardiac device Envelope: insight from real world data. The REINFORCE project.

Author

Ziacchi M, Biffi M, Iacopino S, di Silvestro M, Marchese P, Miscio F, Caccavo VP, Zanotto G, Tomasi L, Dello Russo A, Donazzan L, and Boriani G

Subjects
Humans, Anti-Bacterial Agents therapeutic use, Causality, Defibrillators, Implantable adverse effects, Pacemaker, Artificial adverse effects, Heart Diseases complications, Prosthesis-Related Infections diagnosis, Prosthesis-Related Infections epidemiology, Prosthesis-Related Infections prevention & control
Abstract

Aims: Infections resulting from cardiac implantable electronic device (CIED) implantation are severely impacting on patients' and on health care systems. The use of TYRXTM absorbable antibiotic-eluting envelope has proven to decrease major CIED infections within 12 months of CIED surgery. The aim is to evaluate the impact of the envelope use on infection-related clinical events in a real-world contemporary patient population., Methods and Results: Data on patients undergoing CIED surgery were collected prospectively by participating centers of the One Hospital ClinicalService project. Patients were divided into two groups according to whether TYRXTM absorbable antibiotic-eluting envelope was used or not. Out of 1819 patients, 872 (47.9%) were implanted with an absorbable antibiotic-eluting envelope and included in the Envelope group and 947 (52.1%) patients who did not receive an envelope were included in the Control group. Compared to control, patients in the Envelope group had higher thrombo-embolic or hemorrhagic risk, higher BMI, lower LVEF and more comorbidities. During a mean follow-up of 1.4 years, the incidence of infection-related events was significantly higher in the control compared to the Envelope group (2.4% vs. 0.8%, P = 0.007). The five-year cumulative incidence of infection-related events was 8.1% in the control and 2.1% in the Envelope group (HR: 0.34, 95%CI: 0.14-0.80, P = 0.010)., Conclusion: In our analysis, the use of an absorbable antibiotic-eluting envelope in the general CIED population was associated with a lower risk of systemic and pocket infection., Competing Interests: Conflict of interest: MZ received speaker’s fees from Abbott, Biotronik and Boston Scientific; GB reported small speaker fees from Bayer, Boehringer Ingelheim, Boston, Daiichi Sankyo, Janssen, and Sanofi outside of the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)

Published
2023
Full Text
View/download PDF

49. [The Pacemaker and Implantable Cardioverter-Defibrillator Registry of the Italian Association of Arrhythmology and Cardiac Pacing - Report 2022].

Author

Proclemer A, Zecchin M, Zanotto G, Gregori D, De Ponti R, and D'Onofrio A

Abstract

Background: The Pacemaker (PM) and Implantable Cardioverter-Defibrillator (ICD) Registry of the Italian Association of Arrhythmology and Cardiac Pacing (AIAC) collects information about demographics, clinical characteristics, main indications for PM/ICD therapy and device types from the voluntary Italian collaborating centers., Methods: For the year 2022 main data about national PM and ICD implantation activity were obtained on the basis of European Cards and subsequently analyzed to create a standard report., Results: PM Registry: data about 17 800 PM implantations were collected (14 191 first implants and 3609 replacements). The number of collaborating centers was 152. Median age of treated patients was 81 years (75 quartile I; 86 quartile III). Main ECG indications included atrioventricular conduction disorders in 46.0% of first PM implants, sick sinus syndrome in 17.7%, atrial fibrillation plus bradycardia in 7.7%, other unspecified ECG and electrophysiological abnormalities in 43.0%. For first PM implants, pacing in DDDR mode was reported in 42.2%, followed by DDD mode (20.6%), VVIR mode (25.1%), VVI mode (11.1%) and finally VDD-VDDR (5.1%). Median value of longevity of explanted PMs was 8.3 years. ICD Registry: data about 5210 ICD implantations were obtained (3656 first implants and 1554 replacements). The number of collaborating centers was 301. Median age of treated patients was 72 years (63 quartile I; 79 quartile III). Primary prevention indication was reported in 72.4% of first implants, secondary prevention in 27.6% (cardiac arrest in 4.6% of records). A single-chamber ICD was used in 30.3% of first implants, dual-chamber ICD in 30.0% and biventricular ICD in 39.7%. Median value of longevity of explanted ICDs was 7.0 years., Conclusions: In the calendar year 2022, the Italian PM Registry showed stable electrocardiographic and symptom indications, with an important prevalence of dual-chamber pacing. The ICD Registry documented a large use of prophylactic and biventricular ICDs, reflecting a favorable adherence in clinical practice to trials and guidelines. The ICD longevity and the number of recalls demonstrated a favorable trend.

Published
2023
Full Text
View/download PDF

50. HeartInsight: from SELENE HF to implementation in clinical practice.

Author

Zanotto G and Capucci A

Abstract

There is strong evidence that remote monitoring in cardiac implantable electronic devices can detect device malfunctions earlier than conventional monitoring and that it can be useful for detecting cardiac arrhythmias, while little data are available for an improved management of heart failure (HF). HeartInsight is a new remote monitoring algorithm developed and validated in the SELENE HF study that combines information from a diverse set of sensors integrated into one alert to detect worsening HF with promising accuracy. However, the shift from detecting technical issues or arrhythmia episodes to early predicting clinical events underscores the need to understand how to properly integrate these tools into the clinical workflow by defining an organizational model and shared guidelines for the management of HF alerts. Here, we critically discuss issues that will be raised by the implementation of this 'enhanced' remote monitoring approach to HF care in daily clinical practice., Competing Interests: Conflict of interest: None declared., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results